Humanigen, Inc financial data

Location
830 Morris Turnpike, 4 Th Floor, Short Hills, NJ
State of incorporation
DE
Fiscal year end
December 31
Former names
KALOBIOS PHARMACEUTICALS INC (to 7/17/2017)

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 34.8 % -73.7%
Debt-to-equity -146 % +90.9%
Return On Equity 108 % -96.8%
Return On Assets -234 % -3.97%
Operating Margin -3.06K % +32.8%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 119M shares +68.6%
Common Stock, Shares, Outstanding 119M shares +70.2%
Entity Public Float 84M USD -88.2%
Common Stock, Value, Issued 119K USD +70%
Weighted Average Number of Shares Outstanding, Basic 119M shares +81.6%
Weighted Average Number of Shares Outstanding, Diluted 119M shares +81.6%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 1.7M USD -59%
Research and Development Expense 38.7M USD -77.3%
General and Administrative Expense 15M USD -33.9%
Operating Income (Loss) -52M USD +72.5%
Net Income (Loss) Attributable to Parent -53.6M USD +72.1%
Earnings Per Share, Basic -0.51 USD/shares +83.6%
Earnings Per Share, Diluted -0.51 USD/shares +87.5%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 3.1M USD -95.5%
Assets, Current 5.03M USD -92.9%
Other Assets, Noncurrent 90K USD 0%
Assets 5.12M USD -92.8%
Accounts Payable, Current 38.4M USD -19.8%
Accrued Liabilities, Current 14M USD -26.9%
Liabilities, Current 53.3M USD -25.1%
Liabilities 54.8M USD -43.1%
Retained Earnings (Accumulated Deficit) -686M USD -8.48%
Stockholders' Equity Attributable to Parent -49.7M USD -98.5%
Liabilities and Equity 5.12M USD -92.8%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -7.06M USD +63.7%
Net Cash Provided by (Used in) Financing Activities 18.4M USD -69.9%
Common Stock, Shares Authorized 225M shares 0%
Common Stock, Shares, Issued 119M shares +70.2%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 3.1M USD -95.5%
Interest Paid, Excluding Capitalized Interest, Operating Activities 550K USD +13650%
Deferred Tax Assets, Valuation Allowance 171M USD +13.8%
Deferred Tax Assets, Gross 171M USD +13.8%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.2K USD
Deferred Tax Assets, Operating Loss Carryforwards 151M USD +5.36%
Unrecognized Tax Benefits 1.06M USD 0%
Additional Paid in Capital 636M USD +4.76%
Share-based Payment Arrangement, Expense 5.49M USD -14.2%
Interest Expense 2.2M USD -26.1%